BACKGROUND: Increased mitogen-activated protein kinase (MAPK) phosphorylation has been detected in peripheral nerve of human subjects and animal models with diabetes as well as high-glucose exposed human Schwann cells, and have been implicated in diabetic peripheral neuropathy. In our recent studies, leukocytetype 12/15-lipoxygenase inhibition or gene deficiency alleviated large and small nerve fiber dysfunction, but not intraepidermal nerve fiber loss in streptozotocin-diabetic mice. METHODS: To address a mechanism we evaluated the potential for pharmacological 12/15-lipoxygenase inhibition to counteract excessive MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy. C57Bl6/J mice were made diabetic with streptozotocin and maintained with or without the 12/15-lipoxygenase inhibitor cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC). Human Schwann cells were cultured in 5.5 mM or 30 mM glucose with or without CDC. RESULTS: 12(S) HETE concentrations (ELISA), as well as 12/15-lipoxygenase expression and p38 MAPK, ERK, and SAPK/JNK phosphorylation (all by Western blot analysis) were increased in the peripheral nerve and spinal cord of diabetic mice as well as in high glucose-exposed human Schwann cells. CDC counteracted diabetes-induced increase in 12(S)HETE concentrations (a measure of 12/15-lipoxygenase activity), but not 12/15-lipoxygenase overexpression, in sciatic nerve and spinal cord. The inhibitor blunted excessive p38 MAPK and ERK, but not SAPK/ JNK, phosphorylation in sciatic nerve and high glucose exposed human Schwann cells, but did not affect MAPK, ERK, and SAPK/JNK phosphorylation in spinal cord. CONCLUSION: 12/15-lipoxygenase inhibition counteracts diabetes related MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy and implies that 12/15-lipoxygenase inhibitors may be an effective treatment for diabetic peripheral neuropathy.
BACKGROUND: Increased mitogen-activated protein kinase (MAPK) phosphorylation has been detected in peripheral nerve of human subjects and animal models with diabetes as well as high-glucose exposed human Schwann cells, and have been implicated in diabetic peripheral neuropathy. In our recent studies, leukocytetype 12/15-lipoxygenase inhibition or gene deficiency alleviated large and small nerve fiber dysfunction, but not intraepidermal nerve fiber loss in streptozotocin-diabeticmice. METHODS: To address a mechanism we evaluated the potential for pharmacological 12/15-lipoxygenase inhibition to counteract excessive MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy. C57Bl6/J mice were made diabetic with streptozotocin and maintained with or without the 12/15-lipoxygenase inhibitor cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC). Human Schwann cells were cultured in 5.5 mM or 30 mM glucose with or without CDC. RESULTS: 12(S) HETE concentrations (ELISA), as well as 12/15-lipoxygenase expression and p38 MAPK, ERK, and SAPK/JNK phosphorylation (all by Western blot analysis) were increased in the peripheral nerve and spinal cord of diabeticmice as well as in high glucose-exposed human Schwann cells. CDC counteracted diabetes-induced increase in 12(S)HETE concentrations (a measure of 12/15-lipoxygenase activity), but not 12/15-lipoxygenase overexpression, in sciatic nerve and spinal cord. The inhibitor blunted excessive p38 MAPK and ERK, but not SAPK/ JNK, phosphorylation in sciatic nerve and high glucose exposed human Schwann cells, but did not affect MAPK, ERK, and SAPK/JNK phosphorylation in spinal cord. CONCLUSION:12/15-lipoxygenase inhibition counteracts diabetes related MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy and implies that 12/15-lipoxygenase inhibitors may be an effective treatment for diabetic peripheral neuropathy.
Entities:
Keywords:
Diabetes; Lipoxygenase; Mitogen-Activated Protein Kinase; Neuropathy; Schwann Cells
Authors: Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt Journal: Am J Pathol Date: 2010-08-19 Impact factor: 4.307
Authors: Irina G Obrosova; Jon G Mabley; Zsuzsanna Zsengellér; Tamara Charniauskaya; Omorodola I Abatan; John T Groves; Csaba Szabó Journal: FASEB J Date: 2004-12-20 Impact factor: 5.191
Authors: Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Martin J Stevens; Jerry L Nadler; Irina G Obrosova Journal: Free Radic Biol Med Date: 2010-06-22 Impact factor: 7.376
Authors: Sergey Lupachyk; Hanna Shevalye; Yury Maksimchyk; Viktor R Drel; Irina G Obrosova Journal: Free Radic Biol Med Date: 2011-02-24 Impact factor: 7.376
Authors: Yunpeng Du; Jie Tang; Guangyuan Li; Guanyuan Li; Liliana Berti-Mattera; Chieh Allen Lee; Darian Bartkowski; David Gale; Joe Monahan; Michael R Niesman; Gordon Alton; Timothy S Kern Journal: Invest Ophthalmol Vis Sci Date: 2010-01-13 Impact factor: 4.799
Authors: Kelly B Reilly; Suseela Srinivasan; Melissa E Hatley; Mary Kim Patricia; Joanne Lannigan; David T Bolick; George Vandenhoff; Hong Pei; Rama Natarajan; Jerry L Nadler; Catherine C Hedrick Journal: J Biol Chem Date: 2003-12-15 Impact factor: 5.157
Authors: Aaron P Kellogg; Tim D Wiggin; Dennis D Larkin; John M Hayes; Martin J Stevens; Rodica Pop-Busui Journal: Diabetes Date: 2007-08-24 Impact factor: 9.461
Authors: A D Dobrian; M A Morris; D A Taylor-Fishwick; T R Holman; Y Imai; R G Mirmira; J L Nadler Journal: Pharmacol Ther Date: 2018-10-19 Impact factor: 12.310